UA Home | AHSC | College of Medicine
To Teach To Heal To Discover

hematology/oncology/BMT

Our research team is concentrating its efforts on developing better therapies for children with cancer. These include preclinical studies of novel drugs and vaccines, clinical trials with new agents and innovative approaches in stem cell transplantation.

A novel anti-cancer vaccine (called Chaperone Rich Cell Lysate or CRCL) has been developed in Dr. Emmanuel Katsanis’ laboratory that has been shown to be effective against a variety of tumors in mice. Dr. Katsanis and the scientists in his laboratory are investigating how this vaccine works by analyzing its actions on important immune cells such as T cells, natural killer cells and dendritic cells. The scientific goals of Dr. Katsanis’ tumor immunology program are to understand how CRCL vaccine, which is made up of substances derived from a patient’s cancer cells, stimulates the patient’s immune system to fight its own cancer and prevent it from coming back. This research is critical for the development of effective new immune therapies that can be used in combination with chemotherapy against different cancers.

Nicolas Larmonier, PhD, focuses on understanding the phenomena of tumor-induced immunosuppression and he investigates approaches to override their negative impact on anti-cancer killer cells. A complementary area of his research centers on the optimization and development of cancer vaccines and on the identification of novel cellular actors of the immune system such as Th-17 lymphocytes or killer dendritic cells that may be manipulated to control malignancies. 






Comments to our site editor.

UA College of Medicine : Arizona Health Sciences Center : The University of Arizona

Steele Children's Research Center
1501 N. Campbell Avenue, Suite 3301
PO Box 245073
Tucson, Arizona 85724
Phone: (520) 626-2221

All contents ©2013 Arizona Board of Regents. All rights reserved.
The University of Arizona is an EEO/AA - M/W/D/V Employer.